Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
Retrieved on:
Thursday, December 21, 2023
Health, General Health, Women, Public Relations, Investor Relations, Oncology, Communications, Other Science, Research, Consumer, Science, Clinical Trials, NTRA, MTM, Plasma, Immunotherapy, Patient, Molecular oncology, Nucleic acid thermodynamics, Neoplasm, Circulating tumor DNA, Blood, DNA, MRD, Medical device
To date, mVAF and MTM/mL are the two main metrics that have been used to quantify ctDNA levels in the blood.
Key Points:
- To date, mVAF and MTM/mL are the two main metrics that have been used to quantify ctDNA levels in the blood.
- The premise is that MTM/mL is therefore more representative of a patient’s true disease burden, a hypothesis that was validated in this study.
- Among the 18,426 patients with longitudinal ctDNA measurements, 13.3% had discordant ctDNA trajectories (increase/decrease) when calculated using MTM/mL versus mVAF.
- As the only MRD test that uses MTM/mL, this study supports the utility of Signatera for ctDNA quantification, to measure treatment response at critical time points and inform decisions on how patients are managed.”